# Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

> **NCT02658019** · PHASE2 · COMPLETED · sponsor: **Lynn Feun, MD** · enrollment: 29 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02658019
- **Lead sponsor:** Lynn Feun, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-06
- **Primary completion:** 2019-11-10
- **Final completion:** 2019-12-17
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658019, "Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02658019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*